Head-To-Head Review: Aquestive Therapeutics (NASDAQ:AQST) & Talphera (NASDAQ:TLPH)

Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) and Talphera (NASDAQ:TLPH – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and price targets for Aquestive Therapeutics and Talphera, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aquestive Therapeutics 1 0 3 0 2.50
Talphera 1 1 2 0 2.25

Aquestive Therapeutics presently has a consensus price target of $8.75, indicating a potential upside of 149.57%. Talphera has a consensus price target of $3.00, indicating a potential upside of 270.37%. Given Talphera’s higher probable upside, analysts clearly believe Talphera is more favorable than Aquestive Therapeutics.

Risk & Volatility

Aquestive Therapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500. Comparatively, Talphera has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500.

Profitability

This table compares Aquestive Therapeutics and Talphera’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aquestive Therapeutics -162.33% N/A -57.35%
Talphera N/A -96.70% -53.18%

Valuation and Earnings

This table compares Aquestive Therapeutics and Talphera”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aquestive Therapeutics $44.54 million 9.89 -$83.78 million ($0.64) -5.48
Talphera $30,000.00 1,402.92 -$14.29 million ($0.21) -3.86

Talphera has lower revenue, but higher earnings than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Talphera, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

32.5% of Aquestive Therapeutics shares are owned by institutional investors. Comparatively, 37.7% of Talphera shares are owned by institutional investors. 6.8% of Aquestive Therapeutics shares are owned by insiders. Comparatively, 3.5% of Talphera shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Talphera beats Aquestive Therapeutics on 8 of the 14 factors compared between the two stocks.

About Aquestive Therapeutics

(Get Free Report)

Aquestive Therapeutics is a pharmaceutical company that develops medicines and drug-delivery technologies, with a focus on treatments for central nervous system disorders and severe allergic reactions. Its PharmFilm technology enables medicines to be delivered in dissolvable oral films. The company’s products and product portfolio have included Sympazan, a clobazam oral film for seizures associated with Lennox-Gastaut syndrome, and Libervant, a diazepam buccal film for seizure clusters. Aquestive has also developed film-based medicines with commercial partners, including formulations of Suboxone and Zuplenz.

About Talphera

(Get Free Report)

Talphera, Inc., formerly known as AcelRx Pharmaceuticals, is a specialty pharmaceutical company focused on developing and commercializing treatments for acute pain and critical care. The company’s portfolio includes DSUVIA, a sublingual formulation of sufentanil for the management of acute pain in adults in medically supervised settings. Talphera is also developing Niyad, a nafamostat-based anticoagulant intended for use in extracorporeal circuits during continuous renal replacement therapy. The company’s work in this area is aimed at addressing treatment needs in critical care settings.

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.